Gastric bypass improves beta-cell function but not through increased incretin sensitivity—other mechanisms drive recovery | Research

The takeaway

After Roux-en-Y gastric bypass, beta-cell function improved in T2DM patients but the relative potentiating effects of GLP-1 and GIP were actually reduced, indicating improved glycemic control is driven by enhanced glucose sensitivity and exaggerated postprandial GLP-1 rather than increased incretin sensitivity.

More GLP-1, not better response
Post-RYGB beta-cell improvement comes from dramatically increased GLP-1 production, not enhanced cellular sensitivity to incretins—supporting high-dose GLP-1 pharmacotherapy

What the researchers found

Post-RYGB: GLP-1 and GIP potentiated insulin during hyperglycemia. BUT relative potentiating effects reduced postoperatively: GIP (1st phase) and GLP-1 (1st + 2nd phase). Improved β-cell function driven by: ↑glucose sensitivity + exaggerated postprandial GLP-1 secretion, NOT ↑incretin sensitivity.

Why it matters

Understanding the mechanism behind surgical diabetes remission is essential for developing non-surgical alternatives. This study shows it's about more GLP-1 flooding the system, not better cellular responses to it.

How the study worked

Hyperglycemic clamp studies with GLP-1 and GIP infusion before and after RYGB in T2DM patients. First- and second-phase insulin secretion assessment.

What this study cannot tell us

Small study (not stated in abstract). Clamp conditions are artificial. Results specific to RYGB. GIP receptor desensitization not fully explored.

How to read the evidence

Mechanistic clinical study with hyperglycemic clamp. Gold-standard assessment of beta-cell function.

When this study was published

Published in 2025.

The bigger picture

This challenges the assumption that bariatric surgery restores incretin sensitivity. Instead, the gut remodeling after RYGB simply produces much more GLP-1, overwhelming resistant beta-cells with sheer quantity—a concept that supports high-dose pharmacological GLP-1 therapy.

Questions still open

Does this mean higher GLP-1 drug doses could replicate surgery effects?
Why does incretin sensitivity decrease after surgery despite improved function?
Would drugs that increase endogenous GLP-1 secretion (like DPP-4i) be less effective than exogenous GLP-1?

Common questions

How does gastric bypass fix diabetes?

This study shows it's not by making insulin-producing cells respond better to GLP-1 (incretin sensitivity actually decreased). Instead, the surgically remodeled gut produces much more GLP-1 after eating, and beta-cells also become more responsive to glucose itself. The sheer amount of GLP-1 overcomes resistance.

What does this mean for GLP-1 drug treatment?

It supports using high doses of GLP-1 drugs. If bariatric surgery works by flooding the body with more GLP-1 rather than improving sensitivity to it, then high-dose pharmacological GLP-1 therapy (like semaglutide 2.4 mg) may replicate some surgical benefits through the same mechanism.

Read the original research

β-Cell Function and Sensitivity to Incretins Before and After Roux-en-Y Gastric Bypass in Individuals With Type 2 Diabetes.

Diabetes, 74(9), 1652-1663

View on PubMed ↗Publisher’s paper ↗

Citation

Svane, Maria S; Hindsø, Morten; Martinussen, Christoffer; Dirksen, Carsten; Jørgensen, Nils B; Hedbäck, Nora; Hartmann, Bolette; Kristiansen, Viggo B; Holst, Jens J; Bojsen-Møller, Kirstine N; Madsbad, Sten. (2025). β-Cell Function and Sensitivity to Incretins Before and After Roux-en-Y Gastric Bypass in Individuals With Type 2 Diabetes.. Diabetes, 74(9), 1652-1663. https://doi.org/10.2337/db24-1054